Literature DB >> 11224528

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.

A I Chapoval1, J Ni, J S Lau, R A Wilcox, D B Flies, D Liu, H Dong, G L Sica, G Zhu, K Tamada, L Chen.   

Abstract

We describe here a newly identified member of the human B7 family, designated B7 homolog 3 (B7-H3), that shares 20-27% amino acid identity with other B7 family members. B7-H3 mRNA is not detectable in peripheral blood mononuclear cells, although it is found in various normal tissues and in several tumor cell lines. Expression of B7-H3 protein, however, can be induced on dendritic cells (DCs) and monocytes by inflammatory cytokines and a combination of phorbol myristate acetate (PMA) + ionomycin. Soluble B7-H3 protein binds a putative counter-receptor on activated T cells that is distinct from CD28, cytotoxic T lymphocyte antigen 4 (CTLA-4), inducible costimulator (ICOS) and PD-1. B7-H3 costimulates proliferation of both CD4+ and CD8+ T cells, enhances the induction of cytotoxic T cells and selectively stimulates interferon gamma (IFN-gamma) production in the presence of T cell receptor signaling. In contrast, inclusion of antisense B7-H3 oligonucleotides decreases the expression of B7-H3 on DCs and inhibits IFN-gamma production by DC-stimulated allogeneic T cells.Thus, we describe a newly identified costimulatory pathway that may participate in the regulation of cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11224528     DOI: 10.1038/85339

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  352 in total

Review 1.  Activation and inhibition of lymphocytes by costimulation.

Authors:  Kenneth A Frauwirth; Craig B Thompson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.

Authors:  Hao Liu; Christina Tekle; Yih-Wen Chen; Alexandr Kristian; Yuhua Zhao; Ming Zhou; Zixing Liu; Yan Ding; Bin Wang; Gunhild Mari Mælandsmo; Jahn Marthin Nesland; Oystein Fodstad; Ming Tan
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

Review 3.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

4.  B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.

Authors:  Dong Hua; Jing Sun; Yong Mao; Lu-Jun Chen; Yu-Yu Wu; Xue-Guang Zhang
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 5.  Immunology of B7-H1 and its roles in human diseases.

Authors:  Hideto Tamura; Kiyoyuki Ogata; Haidong Dong; Lieping Chen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

6.  Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.

Authors:  Rebecca Blackstock
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

7.  B7x: a widely expressed B7 family member that inhibits T cell activation.

Authors:  Xingxing Zang; P'ng Loke; Jayon Kim; Kenneth Murphy; Rebecca Waitz; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-14       Impact factor: 11.205

Review 8.  Reflections on CD8 T-cell activation and memory.

Authors:  David Masopust; Rafi Ahmed
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

9.  Murine b7-h3 is a co-stimulatory molecule for T cell activation.

Authors:  Ruhong Yan; Shun Yang; Aiping Gu; Fuqin Zhan; Chunyan He; Chenhao Qin; Xueguang Zhang; Ping Feng
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2013-12

10.  High expression of B7-H3 and CD163 in cancer tissues indicates malignant clinicopathological status and poor prognosis of patients with urothelial cell carcinoma of the bladder.

Authors:  Zhili Xu; Ling Wang; Jianhua Tian; Hongwei Man; Pengfei Li; Baoen Shan
Journal:  Oncol Lett       Date:  2018-03-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.